Educational Objectives | Women's Cancer Symposium | Baptist Health Continuing Medical Education
Skip Ribbon Commands Skip to main content

Women’s Cancer Symposium, Second Annual

2020 | Date and Location TBD

Learn More

2019 Educational Objectives 

Upon completion of this symposium, participants should be better able to:

Recognize the changing landscape of genetic testing. 
Review recent changes in National Comprehensive and Clinical Network (NCCN) guidelines. 
Identify appropriate complexities related to genetic testing.  
Develop an individualized treatment plan in coordination with a patients multi-disciplinary care team. 
Determine when to collect fresh seroma fluid and representative portions of the capsule and send for pathology. 
Describe risks associated with varying breast cancer risk factors. 
Review options for screening among high risk cancer populations. 
Summarize the major changes in ovarian cancer medical care.  
Develop novel effective strategies for newly diagnosed patients. 
Apply improved decision-making regarding treatment options for early stage disease.  
Implement optimized treatment plans of patients with metastatic HER2+ disease.  
Explore the advances and identify the benefits of tomosynthesis and tomosyntheis-guided biopsy. 
Review recent studies and advances involving the utilization of breast MRI. 
Explain the controversy surrounding breast density.
Compare ovarian and tubal cancer cases with and without STIC.  
Identify gynecologic malignancies other than non-uterine serous pelvic carcinomas and benign gynecologic pathologies.  
Identify young adults facing a diagnosis of cancer and implications of the disease and treatment on fertility potential.  
List available options to preserve fertility potential and their advantages and limitations prior to cancer treatment. 
Discuss the most prevalent cancer-related impairments among breast and gynecologic cancer survivors. 
Describe clinical models and treatment strategies to effectively manage the wide spectrum of needs among cancer survivors.  
Define integrative medicine. 
Identify common integrative medicine therapies relevant to cancer care. 
List a few common natural products containing a significant amount of phytoestrogens.  
Create an understanding of the rationale for this new treatment modality. 
List physical and dosimetric advantages.  
Determine appropriate candidates for MRI-linac treatment.
Summarize advantages in implementing MRI-linac based treatments.  
Describe gynecologic cancer-related impairments and their impact on the quality of life for the patient. 
Explain the treatments of gynecologic cancer impairments. 
Identify strategies to minimize barriers to early referral for cancer-related impairments.
Identify indications for autologous versus implant-based breast reconstruction. 
Explain the risks and benefits of nipple-sparing mastectomy.  
Explain strategies to minimize the risk of ALND among clinically node negative but pathologically node positive breast cancer patients. 
Identify the differences in nodal pathologic complete response following neoadjuvant chemotherapy based on tumor receptor profile.  
Implement a working roadmap for implementation of BRCA testing. 
Identify a consortium to guide clinical BRCA issues in ovarian cancer. 
Implement nerve sparing autologous breast reconstruction. 
Assess the use of fat grafting. 
Recognize the changing landscape of genetic testing. 
Identify appropriate complexities related to genetic testing. 
Describe breast cancer related impairments and their impact on the quality of life for the patient. 
Identify strategies to minimize barriers to early referral for cancer related impairments. 
Examine the physician’s role in accessing resources that allow healthcare providers to pursue the mission of curing and preventing breast cancer.